Skip to main content

MoneyWorks4Me

Marksans Pharma informs about press release

05 Nov 2025 Evaluate
Marksans Pharma has informed that (Reuters: MARK.BO; Bloomberg: MRKS IN; NSE: MARKSANS; BSE: 524404) its wholly owned subsidiary Relonchem in UK has received Marketing Authorization for its product Exemestane 25mg film-coated tablets from UK MHRA.

The above information is a part of company’s filings submitted to BSE.  

Peers
Company Name CMP
Sun Pharma. Inds. 1860.00
Dr. Reddys Labs. 1371.20
Cipla 1409.00
Lupin 1990.00
Zydus Lifesciences 1195.00
View more..